Merck & Company, Inc. (MRK – Q3FY20) – KEYTRUDA contributed towards revenue growth.

MRK laboratories made important advances in new product opportunities and development. As an example, during the third quarter, the United States FDA approved an expanded label for KEYTRUDA in the setting of relapsed or refractory classical Hodgkin lymphoma based on KEYNOTE-204 study that compared KEYTRUDA monotherapy to treatment with brentuximab vedotin, a standard therapy.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q3FY20 – Results Overview
– Q3FY20– Segment Performance
– Q3FY20 – R&D Update
– FY20 – Guidance
– Conclusion
– GAAP to Non-GAAP Reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per share Items and Key ratios
– Key Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competition
– Key Developments

Valuation and Consensus Performance

– Relative Valuation
– Analyst Recommendations

Market Price Performance

CrispIdea Coverage

No of Pages : 62